Welcome to our dedicated page for HOOKIPA Pharma news (Ticker: HOOK), a resource for investors and traders seeking the latest updates and insights on HOOKIPA Pharma stock.
HOOKIPA Pharma Inc. (symbol: HOOK) is a clinical-stage biopharmaceutical company dedicated to the development of immunotherapeutics aimed at preventing and treating infectious diseases and cancer. Leveraging its proprietary arenavirus platform, HOOKIPA has created VaxWave® and TheraT®, groundbreaking technologies that reprogram and stimulate the immune system.
VaxWave® is a replication-deficient viral vector, while TheraT® is an attenuated replicating vector. Both technologies are designed to induce strong pathogen-neutralizing antibodies and CD8+ T cells. Remarkably, these vectors can be administered repeatedly without losing efficacy. TheraT® has shown the ability to stimulate CD8+ T cell responses to tumor antigens, achieving frequencies and potencies comparable to or surpassing those seen in adoptive T cell therapy.
HOOKIPA's viral vectors are administered systemically and target dendritic cells in vivo, effectively activating the immune system. This capability is particularly beneficial in the field of immuno-oncology, where it allows for the systemic combating of both primary and metastatic solid tumors.
In recent achievements, HOOKIPA has successfully completed a Phase 1 clinical trial, demonstrating the potential and safety of its innovative approaches. The company continues to focus on advancing its pipeline, which includes the development of an arenavirus-based immunotherapy for KRAS mutant cancer and a neoadjuvant HPV16-specific immunotherapy combined with chemotherapy for HPV16-positive oropharyngeal cancer.
As of December 31, 2023, the company maintains a robust financial position. HOOKIPA remains committed to pioneering immune-based treatments that offer hope for patients with infectious diseases and cancer, positioning itself at the forefront of biopharmaceutical innovation.
HOOKIPA Pharma announced the promotion of Christine D. Baker to Chief Operating Officer effective immediately. With over 30 years in the biotech industry, Baker has significantly contributed to HOOKIPA's strategic business collaborations and the development of its proprietary arenavirus platform. Her leadership is expected to bolster HOOKIPA's growth in novel immunotherapies targeting severe diseases. CEO Joern Aldag commended her experience and commitment to advancing the company's innovative pipeline.
HOOKIPA Pharma (NASDAQ: HOOK) has appointed Tim Reilly, Ph.D., to its Board of Directors, effective immediately. Reilly, a veteran in product development and early clinical trials, will enhance HOOKIPA's oncology initiatives, including the Phase 2 HB-200 program for head and neck cancer and preparations for the HB-300 prostate cancer program. His extensive experience includes 18 years at Bristol Myers Squibb, contributing to 12 therapy approvals. HOOKIPA focuses on innovative immunotherapies utilizing its proprietary arenavirus platform to target various cancers.
HOOKIPA Pharma announced positive preclinical data showcasing potent T cell responses and tumor control against cancer using its arenaviral platform. The results, presented at the AACR Annual Meeting, demonstrate effective combination strategies with 4-1BB agonists and adoptive T cell transfers. The company is preparing to file an IND for its HB-300 program targeting prostate cancer. Biomarker data from the ongoing HB-200 study in HPV16+ head and neck cancers indicate a significant induction of tumor antigen-specific T cell responses, further validating the potential of HOOKIPA's innovative immunotherapies.
HOOKIPA Pharma, a clinical-stage biopharmaceutical company, announced participation in investor meetings at the Kempen Life Sciences Conference in Amsterdam on April 20-21, 2022. The company focuses on developing immunotherapies using its proprietary arenavirus platform, targeting various cancers, including HPV16+ and KRAS-mutated cancers. HOOKIPA aims to advance novel treatments that enhance T cell responses and is also working on functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma reported significant advancements in its oncology pipeline, notably with HB-200, which showed a 75% disease control rate in heavily pre-treated head and neck cancer patients. The candidate received FDA Fast Track designation and has advanced to a Phase 2 trial alongside pembrolizumab. Additionally, a collaboration with Gilead triggered a $54 million commitment. HOOKIPA ended 2021 with a pro forma cash position of $156.9 million. Despite a revenue decrease to $18.4 million in 2021 and a net loss of $75.7 million, the company projects funding into H1 2024, supporting ongoing and new programs.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced the promotion of Klaus Orlinger, Ph.D. to Chief Scientific Officer. Since joining in 2012, Orlinger has significantly contributed to the development of HOOKIPA’s arenavirus platform, enhancing its clinical potential in treating infectious diseases and cancers. CEO Joern Aldag highlighted his expertise and leadership role in advancing the company's immunotherapy initiatives. HOOKIPA continues to develop novel treatments targeting various cancers and aims for functional cures for HBV and HIV in collaboration with Gilead.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced it will release its fourth quarter and full year 2021 financial results on March 24, 2022, before market opening. A live conference call and webcast will take place at 8:30 AM ET to discuss these results and provide updates on corporate developments. HOOKIPA focuses on developing novel immunotherapies utilizing its proprietary arenavirus platform, targeting serious diseases including HPV16+ cancers and collaborating with Gilead on HBV and HIV functional cures.
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced four poster presentations at the 2022 AACR Annual Meeting, showcasing significant preclinical and clinical data on its arenaviral immunotherapy platform. The research emphasizes strong T cell responses, potential drug combinations, and highlights HB-201 and HB-202's efficacy in treating HPV16+ head and neck cancers. The presented abstracts focus on the broad potential of arenaviral vectors in cancer therapy, indicating their capability to activate tumor-specific CD8+ T cells. HOOKIPA's innovative approach aims to enhance cancer treatment outcomes across various malignancies.
HOOKIPA Pharma Inc. (Nasdaq: HOOK) has announced a public offering of 21.7 million shares of common stock priced at $2.00 each and 15,800 shares of non-voting Series A-1 preferred stock at $2,000 each. The total expected proceeds from this offering are approximately $75 million before expenses. The offering is set to close on March 4, 2022, subject to customary conditions, and underwriters have a 30-day option to purchase an additional 5.625 million shares. Proceeds will support HOOKIPA's immunotherapy development pipeline targeting various cancers and diseases.
HOOKIPA Pharma Inc. (Nasdaq: HOOK) announced plans for an underwritten public offering of its common stock and non-voting Series A convertible preferred stock. The offering allows underwriters a 30-day option to buy up to 15% more shares. The offering is subject to market conditions, and terms may vary. Securities offered are under a shelf registration statement, with details to be filed with the SEC. HOOKIPA focuses on immunotherapeutics for severe diseases, including cancer and viral infections.
FAQ
What is the current stock price of HOOKIPA Pharma (HOOK)?
What is the market cap of HOOKIPA Pharma (HOOK)?
What does HOOKIPA Pharma Inc. specialize in?
What are VaxWave® and TheraT®?
How do the arenavirus technologies work?
What recent achievements has HOOKIPA made?
How are HOOKIPA's viral vectors administered?
What is the financial condition of the company?
What is the significance of TheraT® in cancer treatment?
Who can be contacted for investor relations?
What are the upcoming projects for HOOKIPA?
What makes HOOKIPA's technologies unique?
